anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Low back pain (LBP) is a major global disability contributor with profound health and socio-economic implications. The predominant form is non-specific LBP (NSLBP), lacking treatable pathology. Active physical interventions tailored to individual needs and capabilities are crucial for its management. However, the intricate nature of NSLBP and complexity of clinical classification systems necessitating extensive clinical training, hinder customised treatment access. Recent advancements in machine learning and computer vision demonstrate promise in characterising NSLBP altered movement patters through wearable sensors and optical motion capture. This study aimed to develop and evaluate a machine learning model (i.e., 'BACK-to-MOVE') for NSLBP classification trained with expert clinical classification, spinal motion data from a standard video alongside patient-reported outcome measures (PROMs).
METHODS: Synchronised video and three-dimensional (3D) motion data was collected during forward spinal flexion from 83 NSLBP patients. Two physiotherapists independently classified them as motor control impairment (MCI) or movement impairment (MI), with conflicts resolved by a third expert. The Convolutional Neural Networks (CNNs) architecture, HigherHRNet, was chosen for effective pose estimation from video data. The model was validated against 3D motion data (subset of 62) and trained on the freely available MS-COCO dataset for feature extraction. The Back-to-Move classifier underwent fine-tuning through feed-forward neural networks using labelled examples from the training dataset. Evaluation utilised 5-fold cross-validation to assess accuracy, specificity, sensitivity, and F1 measure.
RESULTS: Pose estimation's Mean Square Error of 0.35 degrees against 3D motion data demonstrated strong criterion validity. Back-to-Move proficiently differentiated MI and MCI classes, yielding 93.98% accuracy, 96.49% sensitivity (MI detection), 88.46% specificity (MCI detection), and an F1 measure of .957. Incorporating PROMs curtailed classifier performance (accuracy: 68.67%, sensitivity: 91.23%, specificity: 18.52%, F1: .800).
CONCLUSION: This study is the first to demonstrate automated clinical classification of NSLBP using computer vision and machine learning with standard video data, achieving accuracy comparable to expert consensus. Automated classification of NSLBP based on altered movement patters video-recorded during routine clinical examination could expedite personalised NSLBP rehabilitation management, circumventing existing healthcare constraints. This advancement holds significant promise for patients and healthcare services alike.
BACKGROUND: Pulmonary hypertension (PH) accompanying COPD (PH-COPD) is associated with worse outcomes than COPD alone. There are currently no approved therapies to treat PH-COPD. The PERFECT study (ClinicalTrials.gov: NCT03496623) evaluated the safety and efficacy of inhaled treprostinil (iTRE) in this patient population.
METHODS: Patients with PH-COPD (mean pulmonary arterial pressure ≥30 mmHg and pulmonary vascular resistance ≥4 WU) were enrolled in a multicentre, randomised (1:1), double-blind, placebo-controlled, 12-week, crossover study. A contingent parallel design was also prespecified and implemented, based on a blinded interim analysis of missing data. Patients received treatment with iTRE up to 12 breaths (72 µg) 4 times daily or placebo. The primary efficacy end-point was change in peak 6-min walk distance (6MWD) at week 12.
RESULTS: In total, 76 patients were randomised, 64 in the original crossover design and 12 in the contingent parallel design; 66 patients received iTRE and 58 received placebo. The study was terminated early at the recommendation of the data and safety monitoring committee based on the totality of evidence that iTRE increased the risk of serious adverse events and suggestive evidence of an increased risk of mortality. The change in 6MWD was numerically worse with iTRE exposure than with placebo exposure.
CONCLUSIONS: The risk-benefit observations associated with iTRE in patients with PH-COPD did not support continuation of the PERFECT study. The results of this study do not support iTRE as a viable treatment option in patients with PH-COPD.
A limb tracking biofeedback platform and rehabilitation therapy methodology for spasticity patients improves and maintains limb functionality permitting compliance monitoring, patient encouragement and biofeedback outside the presence of a therapist. The method includes defining a desired therapeutic limb motion, and a goal for repetitions of the therapeutic motion over a given period. The platform includes at least one sensor coupled to the patient's limb which is configured to track at least one of limb movement and orientation. Tracked movement and/or orientation data is transmitted to a platform controller which calculates a number of therapeutic movements of the patient's limb based upon the tracked movement and/or orientation data. Biofeedback to the patient is provided by displaying at least the number of therapeutic movements. Typically reminder prompts and positive reinforcement of goals achieved are also displayed to the patient. The therapist can also have access to the recorded data.
There is a theoretical risk of tumorigenicity due to integration of AAV vector DNA into the genome.

ZOLGENSMA is composed of a recombinant, non-replicating AAV9 vector whose DNA persists largely in episomal form. Random integration of recombinant AAV-vector DNA into human DNA has been reported with ZOLGENSMA and in published literature about other AAV gene therapies. The clinical relevance of individual integration events is unknown, but it is acknowledged that individual integration events could potentially contribute to a risk of tumorigenicity. Cases of tumor have been reported in patients who received ZOLGENSMA post-approval. A causal relationship with ZOLGENSMA has not been established based on tumor analyses. However, in some cases limited information was available. If a tumor develops in a patient receiving ZOLGENSMA, health care providers should contact and report the tumor to Novartis Gene Therapies, Inc. at 1-833-828-3947.
<P>PROBLEM TO BE SOLVED: To find out new functions of Puerariae Flos, to thereby increase the range of uses of the Puerariae Flos and to provide a new improving agent for energy utilization efficiency.  <P>SOLUTION: The improving agent for the energy utilization efficiency is composed of a treated material of the Puerariae Flos. Since the improving agent for the energy utilization efficiency has promoting actions on glucide metabolism and promoting actions on lipid metabolism, e.g. improving actions on exercise capacity or anti-fatigue actions during exercise (explosive power, endurance, etc.) can be possessed. Furthermore, since ingested calories can efficiently be converted into energy, more energy can be consumed during the exercise and effects on prophylaxis or amelioration of obesity, i.e. improving actions on diet effects can be possessed. Since the improving agent for the energy utilization efficiency has excellent promoting actions on the glucide metabolism, the improving agent can further be utilized as an anti-diabetic agent.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Mesenchymal stromal cell (MSC) apoptosis is required for in vivo immunosuppression. However, the induction of apoptosis is heavily dependent on the recipient's immune system. In graft-versus-host disease (GvHD), patients who fail to respond to MSCs are in fact those whose immune cells are unable to induce MSC apoptosis ex vivo. The information is critical to explain why responses in clinical trials vary even though the same sources of MSC products are infused. More importantly, it highlights the need for an alternative MSC treatment for the nonresponders. By using a mouse model of ovalbumin (OVA)-induced allergic inflammation, we demonstrated that we could generate apoptotic MSCs (ApoMSCs) in vitro and use them to successfully reduce allergic airway inflammation. In order to address the logistics of their potential future clinical application, we have shown that ApoMSCs could be cryopreserved without impairing efficacy compared to freshly generated ApoMSCs. We have also highlighted that MSCs need to undergo complete apoptosis before cryopreservation to retain their immunosuppressive activity. The cryopreserved ApoMSCs could serve as a potential future off-the-shelf cellular product, in particular for patients who suffer from inflammatory conditions yet do not harbor the immune capacity to induce MSC apoptosis in vivo. Our data provide proof-of-concept that under laboratory conditions, ApoMSCs can be successfully frozen and thawed without affecting their anti-inflammatory activity, as tested in a murine model of allergic inflammation.
OBJECTIVES: Children with HIV may experience adverse neurocognitive outcomes despite antiretroviral therapy (ART). Cytomegalovirus (CMV) is common in children with HIV. Among children on ART, we examined the influences of early HIV viral load and CMV DNA on neurocognition.
DESIGN: We determined the association between pre-ART viral load, cumulative viral load, and CMV viremia and neurocognition using data from a cohort study.
METHODS: Children who initiated ART before 12 months of age were enrolled from 2007 to 2010 in Nairobi, Kenya. Blood was collected at enrollment and every 6 months thereafter. Four neurocognitive assessments with 12 domains were conducted when children were a median age of 7 years. Primary outcomes included cognitive ability, executive function, attention, and motor z scores. Generalized linear models were used to determine associations between HIV viral load (pre-ART and cumulative; N  = 38) and peak CMV DNA (by 24 months of age; N  = 20) and neurocognitive outcomes.
RESULTS: In adjusted models, higher peak CMV viremia by 24 months of age was associated with lower cognitive ability and motor z scores. Higher pre-ART HIV viral load was associated with lower executive function z scores. Among secondary outcomes, higher pre-ART viral load was associated with lower mean nonverbal and metacognition z scores.
CONCLUSION: Higher pre-ART viral load and CMV DNA in infancy were associated with lower executive function, nonverbal and metacognition scores and cognitive ability and motor scores in childhood, respectively. These findings suggest long-term benefits of early HIV viral suppression and CMV control on neurocognition.
After etching procedure, the enamel and dentin were conditioned with G-aenial adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, G-aenial posterior composite resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
Participants with relapsed or refractory FL will receive 18 weeks of induction treatment with polatuzumab vedotin and venetoclax at the RP2D identified during the dose-escalation phase, in addition to obinutuzumab. Those who achieve CR, PR, or SD at the EOI will be eligible to receive a 24-month maintenance regimen consisting of 8 months of venetoclax and 24 months of obinutuzumab.
The invention discloses an isopentenyl flavonoid compound, a preparation method and application thereof, wherein the compound plays a role in neuroprotection by activating a Keap-Nrf2/HO-1 signal path. The above compound was isolated from Hypericum perforatum (Hypericum perforatum L.) and compound 1 was a novel compound. The neuroprotective activity of compounds 1 and 2 was evaluated by neuroprotection experiments, apoptosis experiments, lactate dehydrogenase inhibition experiments, western blotting experiments, molecular dynamics simulation and zebra fish in vivo models of H  2 O 2  -induced oxidative stress of PC12 cells. Compounds 1 and 2 have significant neuroprotective effects on H  2 O 2  -induced PC12 cells and resist damage from oxidative stress via Keap-Nrf2/HO-1 signaling. In the zebra fish model, the compound 1 obviously inhibits apoptosis of zebra fish brain neuron cells caused by H  2 O 2 . The above results indicate that compound 1, which was first discovered, is a potential neuroprotective lead compound.
ABSTRACT         This specification discloses oral or edible compositions and their manufacture.  It includes foods and pharmaceutical preparations containing sugar and very little water.  In particular it discloses hygienic agents for tooth and mouth care.  It is known that in the oral cavity foodstuffs, beverages and medicaments with a high sugar content lead, in the presence of micro-organisms, to the formation of so-called "plaques" and acid decomposition products which severely attach tooth enamel.  This effect is known by the name caries.  Caries is understood to be an initial attack on the surface of teeth which are then progressively destroyed by cavities being formed therein.  Thus the specification discloses an edible or oral composition which composition contains sugar and very little water and having a content of the enzymes lactate dehydrogenase and saccharose - inverting enzyme which limits promotion of tooth decay.  It appears that by adding lactate dehydrogenase in combination with a sucrose-inverting enzyme, an inhibition system is incorporated into foodstuffs and con-fectionery of low water content or containing no water, and when these products are eaten, this system counteracts the harmful effect, in the presence of cariogenic bacteria, of the products formed by the decomposition of sugars, and converts the food-stuffs, in particular confectionery, and the pharmaceutical preparations into non-cariogenic or anticariogenic foodstuffs and pharmaceutical preparations which are not harmful to teeth.          This preferably comprises foodstuffs with a residual moisture content of 0.1 to 2%.  It includes foodstuffs which contain a proportion of naturally occurring sugars, such as sucrose, glucose, fructose and the like, as well as sugar alcohols, as - a -sugar substitutes.  Foodstuffs containing sucrose are particularly preferred.  If appropriate, foodstuffs or con-fectionery or pharmaceutical preparations which contain no customary sugars can be used.  These can be materials which are sweetened on the basis of sugar substitutes, for example saccharin, cyclamate, protein sweeteners extracted from tropical plants, xylitol and the like.  The sugar containing foodstuff is intended in particular to comprise confectionery, such as bakery products, sweets, chewing gum, etc.     - b -
The prevention and treatment type pure traditional Chinese medicine livestock and poultry feed additive composition comprises the following components in parts by weight: 3-9 parts of coptis chinensis (or fructus forsythiae or rheum officinale), 15-25 parts of rhizoma phragmitis (or rhizoma imperatae or polygonatum odoratum), 3-9 parts of scutellaria baicalensis, 9-15 parts of radix paeoniae alba, 3-9 parts of honey-fried licorice root, 3-9 parts of Chinese date (or black date or red date), 3-9 parts of ginger, 6-12 parts of rhizoma acori graminei, 12-18 parts of rhizoma pinellinae praeparata, 3-9 parts of fructus gardeniae, 5-15 parts of fermented soya beans and 3-9. Adding 10-16g of the traditional Chinese medicine composition into drinking water for poultry per kilogram, uniformly mixing, standing for 1 hour, boiling, keeping the boiling state for 20-40 minutes, taking supernate, cooling to room temperature for poultry drinking, and cooling to room temperature for 2-3 times per day. The invention has good treatment and prevention effects on common poultry diseases such as cholera fowl, pullorum disease, typhoid fever and diarrhea. The natural plant specific active ingredients directly or indirectly inhibit and kill viruses, so that the antibacterial effect is strong, the antibacterial spectrum is wide, and the effect on poultry gastrointestinal diseases is particularly remarkable; meanwhile, the poultry is immunoregulated, the disease resistance of the poultry is enhanced, and the survival rate is improved. The formula of the medicine takes bitter cold and purgation-lowering herbs as well as pungent and warm herbs to dispel dampness, bitter cold and lower heat, so as to play the roles of clearing heat and resolving dampness, regulating qi and regulating the middle warmer. The compatibility of the cold and heat in the formula reflects the treatment concept of opposite composition and parallel treatment in traditional Chinese medicine.
INTRODUCTION: Hereditary angioedema (HAE) is a potentially life-threatening genetic disorder characterized by recurrent episodes of angioedema. From the onset of symptoms until diagnosis, patients often have several contacts with the healthcare system. It was hypothesized that a "digital fingerprint" of undiagnosed HAE patients could be identified in Danish registries.
METHODS: This study compared patients with a control group of patients with a diagnosis of Quincke's edema (QE) or bee/wasp allergy because they could have phenotypic similarities.
RESULTS: QE was the most common diagnosis code in the hospital sector among HAE patients before a specific diagnosis of HAE was established. HAE patients had been seen at the hospital on average once every other year before the diagnosis was established, and on average once during the year before the diagnosis was established. Many patients contacted a practicing dermatologist during the year before the diagnosis was established.
CONCLUSIONS: HAE patients had several hospital contacts due to swelling attacks during the years before their diagnosis was established, and half of them consulted a dermatologist. It was not possible to identify a specific "digital fingerprint" in Danish registries regarding specific procedures or diagnoses distinguishing them from the control group. It is therefore recommended that hospitalized patients with angioedema of unknown cause be screened for HAE.
The medical system architecture includes an arrangement of modules (1 to 4) for the registration of images, a device (5 to 8, 11, 12) for the processing of the images and a device (9) for the transmission of the images. The device for the image processing comprises a digital image system with a computer, which works according to a method for data exchange between different application programs (OLE) with graphic control elements.  An industry standard for the transmission of images and further medical information between computers, pref. the DICOM standard, is implemented as a software component in combination with a Scripting-Language technology for navigation, to enable the digital communication between the modules of different manufacturers. The implementation may be performed, e.g. through Visual Basic, Active X, Opendoc Script, JAVA, JAVA Script, CORBA or CORBA-DII.
The processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) occur concurrently. This constant protein turnover allows the muscle fiber to change its protein structure if loading demands or diet changes. The plasticity of skeletal muscle to respond to altered loading and contractile patterns is evidence of the capacity for remodeling that a fiber can undergo. It is quite well documented for example that mitochondrial content increases with endurance-type work. In contrast, heavier loading leads to less change in mitochondrial content but increases in myofibrillar proteins. All of the aforementioned phenotypic adaptations represent a re-patterning of the muscle's genetic expression patterns, protein translation, and processes for breakdown of existing protein structures to 'insert' the new proteins. A persistent muscle protein turnover also provides for a constant mechanism of protein 'maintenance' by removing damaged proteins and replacing them with new proteins. Damage to proteins can come about through oxidation or simply mechanical damage due to high forces during lengthening contractions. Regardless of the mechanism the balance between the processes of muscle protein synthesis (MPS) and muscle protein breakdown (MPB) will determine the net gain, loss, or no change of proteins in the myofiber.
A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions. The onset of symptoms usually occurred within hours (most commonly 1 to 4 hours) following the administration of contrast media. These reactions include fever, chills, nausea, vomiting, pruritus, rash, diarrhea, hypotension, edema, and oliguria. Some clinicians have noted that these reactions resemble the immediate side effects caused by interleukin-2 administration, however the cause of contrast reactions after interleukin-2 therapy is unknown. Most events were reported to occur when contrast media was given within 4 weeks after the last dose of interleukin-2. These events were also reported to occur when contrast media was given several months after interleukin-2 treatment.13
A personal medical console (e.g. patient server 120) is connectable to a plurality of different sensor devices (ECG, Oxymetery, blood pressure etc.) and different effector devices (e.g. treatment device, infusion pump, ventilator etc.) and configured to monitor operation of one or more sensor devices and control operation of one or more effector devices. The sensor devices sense physiological characteristics. The medical console is configured to receive sensor data from sensor devices and output control data defining one or more actions for controlling the one or more of the effector devices. An analysis engine in the medical console is configured to process the sensor data received from the one or more sensor devices and output control data in response to the sensor data by determining a divergence of the sensor data to a target health state, and generating the control data for the one or more effector devices responsive to the divergence. The patient server may also use plug and play technology (PnP). In an alternative embodiment an interface adapter may translate data from a sensor device into an appropriate format for communication to the patient server. In another embodiment a medical console determines a secondary physiological characteristic from a combination of medical device data and visualises the data.
The invention discloses an acupoint plaster for treating spontaneous perspiration, night sweat and hidrosis. The acupoint plaster is prepared from the following components in weight proportion: 9 to 11g of radix curcumae, 9 to 11g of astragalus mongholicus, and 4 to 6g of halloysitum rubrum. A preparation method of the acupoint plaster comprises the following steps: selecting pure medicaments, namely radix curcumae, astragalus mongholicus and halloysitum rubrum, and grinding into fine powder in a proportion; filling into a bottle for later use; and uniformly mixing a proper amount of prepared medicinal powder into paste with honey. The acupoint plaster is used by placing a proper amount of paste on a small adhesive tape, applying the plaster to two nipples for 24 hours, and changing another plaster when the plaster is taken off. Sweat is reduced generally after the plaster is used once, and spontaneous perspiration, night sweat and hidrosis can be basically cured after three times of application. The acupoint plaster for treating spontaneous perspiration, night sweat and hidrosis has the characteristics of convenience in use, quick curative effect and high cure rate, and can effectively prevent and treat series of diseases caused by sweating without any toxic or side effect.